Actively Recruiting
Phase II Study of Pembrolizumab and Enfortumab Vedotin Before and After Kidney and Ureter Removal Surgery for High-Risk Upper Tract Urothelial Cancer
Led by Jonsson Comprehensive Cancer Center · Updated on 2026-07-16
21
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how well pembrolizumab combined with enfortumab vedotin works when given before and after radical nephroureterectomy surgery for patients with high-risk upper tract urothelial cancer. This phase II trial aims to measure the tumors response to treatment and assess how long patients remain free of cancer recurrence after surgery. The study also explores potential markers and imaging techniques that may predict treatment response, while monitoring side effects and surgical complications. Participants receive pembrolizumab and enfortumab vedotin intravenously before surgery to possibly shrink the tumor and reduce the amount of tissue removed. After surgery, they receive additional pembrolizumab treatments. Throughout the study, patients undergo radical nephroureterectomy, magnetic resonance urography imaging, and provide blood, urine, and tissue samples for analysis. During the trial, participants are closely monitored with imaging and laboratory tests to assess their response and collect biomarkers. Researchers track the occurrence of side effects, surgical recovery, and how long patients remain cancer-free after surgery, with follow-up lasting up to one year post-operation. The studys total duration includes pre-surgery treatment, surgery, post-surgery therapy, and ongoing assessments to understand treatment effects and safety.
CONDITIONS
Brief Title
Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer
Research Team
A
Ankush Sachdeva
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here